Kishida H, Murao S
Clin Pharmacol Ther. 1987 Aug;42(2):166-74. doi: 10.1038/clpt.1987.127.
The effect of nicorandil, a new coronary vasodilator, was evaluated in 32 patients with variant angina pectoris in a single-blind trial. The study was comprised of a pretreatment period of 2 days with a placebo, a 3-day nicorandil medication period (20 mg/day), and a 2-day posttreatment period with the placebo. Anginal attacks disappeared completely in 24 of the 32 patients. The number of attacks during the pretreatment period, 3.6 +/- 0.4 per day, became significantly reduced to 0.7 +/- 0.2 per day during nicorandil therapy (P less than 0.001) and significantly increased to 1.3 +/- 0.3 per day after withdrawal of the drug (P less than 0.05). In 17 patients with continuous ECG monitoring, the frequency of occurrence of ST-segment elevation was 8.6 +/- 2.7 per day during the preobservation period, significantly decreased to 0.4 +/- 0.2 per day during nicorandil therapy (P less than 0.01), and significantly increased to 1.9 +/- 0.7 per day after withdrawal of the drug (P less than 0.05). The results demonstrate the effectiveness of nicorandil in the treatment of variant angina pectoris.
在一项单盲试验中，对32例变异型心绞痛患者评估了新型冠状动脉扩张剂尼可地尔的疗效。该研究包括2天的安慰剂预处理期、3天的尼可地尔用药期（20毫克/天）以及2天的安慰剂治疗后期。32例患者中有24例心绞痛发作完全消失。预处理期每天发作次数为3.6±0.4次，在尼可地尔治疗期间显著减少至每天0.7±0.2次（P＜0.001），停药后显著增加至每天1.3±0.3次（P＜0.05）。在17例持续进行心电图监测的患者中，观察前期ST段抬高的发生频率为每天8.6±2.7次，在尼可地尔治疗期间显著降至每天0.4±0.2次（P＜0.01），停药后显著增加至每天1.9±�0.7次（P＜0.05）。结果表明尼可地尔治疗变异型心绞痛有效。
